- A laboratory quality control study evaluates technician performance in reading test results. Technician X achieves AUC = 0.88 while Technician Y achieves AUC = 0.72, both reading the same 100 positive and 100 negative samples. What does this suggest about the training needs?
Answer: Technician Y needs additional training, as the large AUC difference indicates substantially poorer discriminatory ability
When you encounter AUC (Area Under the Curve) values in biostatistics, you're dealing with a measure of diagnostic accuracy that ranges from 0.5 (no discriminatory ability) to 1.0 (perfect discrimination). The key insight is that meaningful differences in AUC values reflect real differences in performance quality.
The 0.16 difference between Technician X (AUC = 0.88) and Technician Y (AUC = 0.72) represents a substantial gap in discriminatory ability. Technician X demonstrates "good" performance (0.80-0.90 range), while Technician Y shows only "fair" performance (0.70-0.80 range). This difference translates to measurably different abilities to correctly distinguish between positive and negative samples, indicating that Technician Y would benefit from additional training to improve their diagnostic accuracy.
Option B incorrectly assumes that exceeding 0.70 means "adequate" performance without considering relative differences. While 0.70 might be a minimum threshold, the substantial performance gap suggests room for improvement. Option C misinterprets higher AUC values - an AUC of 0.88 indicates better overall discrimination, not overcalling positives (which would actually lower AUC through increased false positives). Option D commits a logical error by suggesting that reading the same samples makes performance differences meaningless - in fact, using identical samples makes the performance comparison more valid and interpretable.
Study tip: Remember that AUC differences of 0.10 or more typically represent clinically meaningful performance gaps. Don't just look at whether values exceed thresholds - compare the actual discriminatory abilities they represent.
- In ROC analysis, what is the primary advantage of using AUC over selecting a single sensitivity-specificity pair to evaluate test performance?
Answer: AUC provides a threshold-independent summary of discriminatory ability across all possible operating points
ROC analysis evaluates how well a diagnostic test distinguishes between diseased and non-diseased individuals across all possible threshold values. When you encounter ROC questions, focus on understanding what makes one summary measure superior to another for capturing overall test performance.
The Area Under the Curve (AUC) provides a comprehensive, threshold-independent assessment of a test's discriminatory ability. Unlike selecting a single sensitivity-specificity pair, which only tells you how the test performs at one specific cutpoint, AUC summarizes performance across every possible threshold. This gives you a complete picture of the test's ability to distinguish between positive and negative cases, regardless of where you might set the decision boundary. An AUC of 0.5 indicates no discriminatory ability (random guessing), while 1.0 represents perfect discrimination.
Choice B is incorrect because AUC calculation is actually more complex than computing sensitivity and specificity at a single threshold—it requires integration across the entire ROC curve. Choice C misrepresents AUC's purpose; while AUC tells you how well a test discriminates overall, it doesn't identify the optimal threshold, which depends on clinical considerations like the relative costs of false positives versus false negatives. Choice D is wrong because AUC doesn't adjust for disease prevalence—that's a separate consideration when interpreting positive and negative predictive values.
Study tip: Remember that AUC's key strength is being threshold-independent. When comparing diagnostic tests, AUC lets you assess overall discriminatory performance without having to pick arbitrary cutpoints, making it the gold standard for test comparison.
- Two biomarkers (A and B) for predicting cardiovascular events have AUC values of 0.72 and 0.68, respectively. If biomarker A has a sensitivity of 80% at a specificity of 60%, and biomarker B has a sensitivity of 75% at a specificity of 65%, which statement about their ROC curves is most accurate?
Answer: The curves must intersect since biomarker B has higher specificity at the given operating point
ROC curves can intersect even when one biomarker has a higher overall AUC. At the given operating points, biomarker A has (1-specificity, sensitivity) = (0.40, 0.80) while biomarker B has (0.35, 0.75). Since biomarker B achieves higher specificity (lower false positive rate) at a comparable sensitivity level, while biomarker A has the higher overall AUC, the curves must cross at some point. Choice A is incorrect because curves can intersect despite different AUCs. Choice C is wrong because AUC represents overall performance, not superiority at every threshold. Choice D is irrelevant to whether curves can intersect.
- Two screening tests are compared using ROC analysis. Test A has AUC = 0.82 and Test B has AUC = 0.76. At a specificity of 0.80, Test A has sensitivity of 0.65 while Test B has sensitivity of 0.70. Which statement best describes the comparison of these tests?
Answer: Test A is superior overall, but Test B performs better at this specific operating point with 80% specificity
When you encounter ROC analysis questions, you need to distinguish between overall test performance (measured by AUC) and performance at specific operating points (sensitivity/specificity pairs).
The Area Under the Curve (AUC) represents overall discriminatory ability across all possible thresholds. Test A's AUC of 0.82 is higher than Test B's 0.76, indicating that Test A performs better overall. An AUC closer to 1.0 means the test can better distinguish between diseased and non-diseased individuals across the full range of cut-off values.
However, at the specific operating point where specificity = 0.80, Test B achieves higher sensitivity (0.70 vs 0.65). This means that when both tests are calibrated to correctly identify 80% of non-diseased individuals, Test B correctly identifies more diseased individuals than Test A at this particular threshold.
Option A correctly captures both aspects: Test A is superior overall (higher AUC) but Test B performs better at this specific operating point (higher sensitivity at 80% specificity).
Option B incorrectly suggests Test B is superior overall, ignoring the AUC comparison. Option C wrongly dismisses the practical importance of performance at specific operating points – in clinical practice, you often need to operate at particular sensitivity/specificity combinations. Option D is incorrect because a 0.06 difference in AUC is typically considered clinically meaningful, and the question asks about comparison, not statistical significance.
Remember: AUC shows overall performance across all thresholds, but individual operating points matter for practical clinical decision-making. Both perspectives are valuable for test evaluation.
- A medical device company claims their new test has 'superior discrimination' with AUC = 0.83 compared to the standard test's AUC = 0.78. The 95% confidence intervals are (0.77-0.89) and (0.72-0.84) respectively, based on independent studies. What is the most accurate assessment?
Answer: The confidence intervals overlap substantially, so statistical significance of the difference cannot be determined without direct comparison
When evaluating diagnostic test performance, you need to understand that comparing AUC values from independent studies requires careful statistical consideration, not just visual inspection of overlapping confidence intervals.
The correct approach here is answer A. While the confidence intervals do overlap, this alone doesn't tell you whether the difference between tests is statistically significant. To properly compare these AUC values, you'd need a direct head-to-head study comparing both tests on the same population, which would allow calculation of the confidence interval for the actual difference between AUC values. The overlapping intervals from independent studies create uncertainty about the true difference.
Answer B commits a logical error by comparing the new test's lower bound (0.77) to the standard test's point estimate (0.78). This isn't a valid statistical comparison—you can't mix confidence bounds from one test with point estimates from another to determine significance.
Answer C makes the common misconception that overlapping confidence intervals automatically mean "no significant difference." This isn't necessarily true, especially when comparing results from independent studies rather than calculating the confidence interval of the actual difference.
Answer D is factually incorrect since 0.83 does not exceed 0.84.
Study tip: When comparing diagnostic tests, remember that overlapping confidence intervals from separate studies don't definitively prove equivalence or difference. Look for direct comparison studies or explicit statistical tests of the difference between measures. This distinction frequently appears on biostatistics exams.
- Study the ROC curves for three diagnostic tests shown. Which statement best describes the relative performance of these tests?
Answer: Test 1 has the highest AUC, Test 2 is intermediate, and Test 3 performs poorly with AUC near 0.5
Test 1 (solid line) curves closest to the upper-left corner with the largest area underneath, indicating highest AUC. Test 2 (dashed line) shows intermediate performance. Test 3 (dotted line) closely follows the diagonal, indicating poor discrimination with AUC ≈ 0.5. Choice B incorrectly interprets the shape. Choice C misunderstands that Test 3's poor performance doesn't represent 'maintaining high specificity.' Choice D incorrectly suggests all ROC curves have equal AUC. Choice E misinterprets Test 1's superior performance.
- A screening test ROC curve shows that at a false positive rate of 0.20, the true positive rate is 0.75. At a false positive rate of 0.10, the true positive rate is 0.60. What can be concluded about the test performance in this range?
Answer: The test shows good discrimination with a reasonable trade-off between sensitivity and specificity in this range
When you encounter ROC curve analysis questions, focus on understanding the fundamental trade-off between sensitivity (true positive rate) and specificity, and what constitutes reasonable test performance.
Let's examine what these data points tell us. At a false positive rate of 0.20, the specificity is 0.80 (since specificity = 1 - false positive rate), with sensitivity of 0.75. At a false positive rate of 0.10, specificity increases to 0.90, while sensitivity drops to 0.60. This represents a typical ROC curve behavior where increasing specificity comes at the cost of decreased sensitivity.
The key insight is that both operating points show strong performance. A sensitivity of 75% with specificity of 80% is quite good, as is 60% sensitivity with 90% specificity. The test maintains reasonable diagnostic ability across this range, making answer A correct.
Answer B reflects a fundamental misunderstanding - it's normal and expected for sensitivity to decrease when false positive rate decreases (specificity increases). This trade-off doesn't indicate poor discrimination; it's inherent to diagnostic testing.
Answer C incorrectly assumes that maximizing specificity automatically makes a test optimal. The optimal operating point depends on the clinical context and relative costs of false positives versus false negatives.
Answer D is wrong because you can evaluate test performance from limited ROC data points. While the complete curve provides more information, these two points clearly demonstrate acceptable discrimination ability.
Remember: Good ROC performance isn't about avoiding the sensitivity-specificity trade-off, but rather maintaining reasonable values for both across different operating points.
- An ROC analysis comparing a new rapid test to a gold standard shows an AUC of 0.58 with a 95% confidence interval of (0.52, 0.64). The study included 200 diseased and 300 non-diseased subjects. Which conclusion is most appropriate?
Answer: The confidence interval suggests the test may have modest diagnostic utility requiring validation
When interpreting ROC analysis results, you need to evaluate both the AUC value and its confidence interval to understand diagnostic performance and statistical significance.
An AUC of 0.58 indicates weak diagnostic ability - it's only slightly better than random chance (AUC = 0.50). However, the key insight lies in the confidence interval (0.52, 0.64). Since this interval includes 0.50, the test's performance is not statistically significantly different from random guessing. Yet because the interval extends to 0.64, there's potential for modest diagnostic utility that warrants further investigation.
Option A correctly captures this nuanced interpretation - the confidence interval suggests possible modest utility while acknowledging the need for validation studies.
Option B is incorrect because while the test shows poor performance, you can't definitively conclude "no diagnostic value" when the upper confidence bound reaches 0.64. The statistical evidence is inconclusive rather than definitively negative.
Option C misinterprets statistical significance. For an AUC to be statistically significant, the entire confidence interval must exclude 0.50, not just the lower bound exceeding it. Here, 0.50 falls within the interval.
Option D commits a fundamental error by confusing sample size with diagnostic accuracy. A large sample size improves precision of estimates but doesn't validate clinical meaningfulness - a precisely measured poor test is still poor.
Study tip: In ROC analysis, always check whether the confidence interval excludes 0.50 to determine statistical significance, and remember that statistical significance doesn't automatically equal clinical utility.
- In comparing three diagnostic tests with AUC values of 0.72, 0.68, and 0.75, a researcher wants to determine if the differences are statistically significant. What additional information is most critical for this comparison?
Answer: The confidence intervals for each AUC and whether the same subjects were tested with all three methods
When comparing diagnostic tests using AUC (Area Under the Curve) values, you're essentially asking whether observed differences reflect true performance differences or just random variation. This requires proper statistical testing, not just eyeballing the numbers.
Answer A is correct because statistical comparison of AUC values requires two critical pieces of information. First, you need confidence intervals to determine if the AUC differences are statistically significant—overlapping confidence intervals suggest no meaningful difference, while non-overlapping intervals indicate significant differences. Second, whether the same subjects were tested with all methods determines your statistical approach: paired tests (same subjects) versus independent tests (different subjects) use entirely different methodologies and have different statistical power.
Answer B is wrong because sensitivity and specificity at optimal cut-points don't help determine statistical significance of AUC differences. These are descriptive statistics that characterize test performance but don't provide the variability measures needed for significance testing.
Answer C is incorrect because disease prevalence affects positive and negative predictive values, but AUC is inherently independent of prevalence—it measures the test's ability to discriminate between diseased and non-diseased individuals regardless of how common the disease is.
Answer D is wrong because cost-effectiveness analysis is about practical implementation decisions, not statistical significance of diagnostic performance differences.
Study tip: Remember that comparing any statistical measures requires information about variability (confidence intervals) and study design (paired vs. independent). AUC comparisons are no exception—you need both the uncertainty measures and the correlation structure to test properly.
- A research team compares ROC curves for predicting treatment response using clinical variables alone (AUC = 0.67) versus clinical variables plus genetic markers (AUC = 0.74). Both models were tested on the same 200 patients. What statistical approach is most appropriate to test if this improvement is significant?
Answer: Paired comparison test for correlated AUC values since the same patients were used for both models
When comparing ROC curves derived from the same dataset, you're dealing with correlated rather than independent measurements. Since both models (clinical variables alone vs. clinical + genetic) were evaluated on the identical 200 patients, their AUC values are inherently linked—each patient contributes to both AUC calculations.
Answer A is correct because paired comparison tests (like the DeLong test) are specifically designed for correlated AUC values. These tests account for the correlation structure when the same subjects generate both ROC curves, providing appropriate standard errors and p-values for the AUC difference.
Answer B is wrong because an independent samples t-test assumes the two groups are unrelated. This ignores the correlation between AUCs from the same patients, leading to incorrect standard errors and potentially invalid conclusions about significance.
Answer C is wrong because while chi-square tests can compare sensitivity and specificity at specific thresholds, they don't evaluate the overall discriminative ability across all possible thresholds like AUC does. You'd lose the comprehensive performance comparison that ROC analysis provides.
Answer D is wrong because Fisher's exact test compares categorical outcomes between groups, but you're not comparing patient groups—you're comparing the performance of two prediction models on the same patients. This approach doesn't address model discrimination ability.
Study tip: Whenever you see ROC curve comparisons on the same dataset, immediately think "correlated data = paired test." The key word is "same patients"—this signals you need a test that accounts for the inherent correlation between the measurements.
- A screening test for diabetes has been evaluated in two populations. In Population A (high diabetes prevalence), AUC = 0.79. In Population B (low diabetes prevalence), AUC = 0.81. What explains this difference?
Answer: The difference is likely due to random variation or different case mix; prevalence should not affect AUC
When you encounter questions about AUC (Area Under the Curve) across different populations, remember that AUC measures a test's inherent discriminatory ability - its capacity to distinguish between those with and without the condition. This intrinsic property should remain consistent regardless of disease prevalence.
The correct answer is A because AUC is prevalence-independent by design. It evaluates how well a test ranks patients across all possible threshold values, which depends on the test's biological accuracy, not the population's disease frequency. The small difference between 0.79 and 0.81 likely reflects random sampling variation, different case severity distributions, or minor population characteristics - not a systematic effect of prevalence.
Option B incorrectly assumes prevalence affects specificity in a way that changes AUC. While prevalence influences positive and negative predictive values, it doesn't systematically alter the test's true positive and false positive rates that determine AUC. Option C makes the opposite error, suggesting high prevalence somehow reduces discriminatory ability - but AUC measures the test's ranking performance, not prevalence-dependent metrics. Option D reflects a common misconception about screening effectiveness; while screening programs may be more cost-effective in high-prevalence populations, the test's discriminatory performance (AUC) remains unchanged.
Study tip: Remember the distinction between prevalence-dependent measures (PPV, NPV) and prevalence-independent measures (sensitivity, specificity, AUC). When you see AUC comparisons across populations with different prevalences, think "random variation" rather than systematic prevalence effects.
- Three independent diagnostic tests for the same condition have AUC values of 0.82, 0.78, and 0.75. A clinician proposes combining all three tests by requiring at least two positive results for a positive diagnosis. Compared to using the best single test, this combination strategy will most likely:
Answer: Increase specificity but decrease sensitivity compared to the best individual test
A 'majority rule' combination (≥2 of 3 positive) typically increases specificity because it requires multiple confirmations, reducing false positives. However, it usually decreases sensitivity because true cases need multiple tests to be positive, increasing the chance of missing cases where only one test detects the condition. Choice A is incorrect because both metrics rarely improve simultaneously with this strategy. Choice C is wrong because combination strategies can change overall performance. Choice D is incorrect because specificity typically improves with this approach.
- A laboratory develops a new biomarker test and reports an AUC of 0.91 based on a study with 50 cases and 950 controls. What is the primary concern with interpreting this result?
Answer: The highly imbalanced case-control ratio may lead to overly optimistic AUC estimates and poor generalizability
When evaluating diagnostic test performance, you need to consider not just the AUC value itself, but the study design that produced it. The Area Under the Curve (AUC) measures how well a test distinguishes between cases and controls, but highly imbalanced datasets can create misleading results.
With only 50 cases versus 950 controls (a 1:19 ratio), this study has severe class imbalance. Such extreme imbalance often leads to overly optimistic performance metrics because the test appears to perform well simply by correctly identifying the abundant control group. More critically, this ratio rarely reflects real-world disease prevalence, making the results difficult to generalize to actual clinical populations where the case-to-control ratio would be different.
Looking at the wrong answers: B is incorrect because sample size of 50 cases, while not ideal, is sufficient for AUC calculation—there's no statistical rule preventing reliable AUC estimation above 0.90 with this sample size. C is wrong because AUC values of 0.91 are achievable and clinically realistic for well-performing biomarkers; many FDA-approved diagnostic tests have AUCs in this range. D is false because AUC can be calculated with any number of cases and controls—the "100 cases minimum" is not a statistical requirement for AUC computation.
The correct answer is A because the imbalanced design is the primary methodological concern that would make you question the validity and generalizability of these results.
Study tip: When evaluating diagnostic test studies, always check the case-to-control ratio first. Extreme imbalances should raise red flags about the reliability and real-world applicability of the reported performance metrics.
- A screening program needs to minimize false positives due to limited follow-up resources. Using the ROC curve data shown in the table, which threshold provides the best balance of high specificity (≥0.85) while maintaining reasonable sensitivity?
Answer: Threshold C: Sensitivity = 0.70, Specificity = 0.85
Threshold C meets the specificity requirement of ≥0.85 while maintaining the highest sensitivity (0.70) among the qualifying options. Choice B doesn't meet the specificity requirement (0.75 < 0.85). Choice D has higher specificity but lower sensitivity (0.60 vs 0.70). Choice A has high sensitivity but fails the specificity requirement. Choice E has very high specificity but unacceptably low sensitivity for most screening purposes.
- Two radiologists independently interpret the same set of mammograms. Radiologist A has AUC = 0.78 and Radiologist B has AUC = 0.74. A combined reading strategy where a positive result from either radiologist triggers recall has AUC = 0.81. What does this suggest about the diagnostic strategies?
Answer: The combined strategy improves overall performance, likely by increasing sensitivity at the cost of some specificity
When evaluating combined diagnostic strategies in ROC analysis, focus on how the combination affects the sensitivity-specificity trade-off and overall discriminative ability.
The key insight here is understanding what an "either positive" strategy does. When either radiologist's positive result triggers recall, you're essentially lowering the threshold for a positive diagnosis. This increases sensitivity (fewer missed cancers) because a case is called positive if either reader detects it, but decreases specificity (more false positives) because either reader's false positive will trigger recall. The net effect shows improved overall discrimination (AUC increased from 0.78 to 0.81), indicating the combined approach captures more true positives than the additional false positives it creates.
Option A correctly identifies this sensitivity-specificity trade-off and recognizes that the improved AUC demonstrates better overall performance. Option B incorrectly suggests the improvement isn't meaningful—any AUC increase represents better discrimination, and 0.03 can be clinically significant in cancer screening. Option C makes a flawed recommendation by ignoring that the combined strategy actually outperforms either individual radiologist. Option D is clearly wrong since the radiologists have different AUCs (0.78 vs 0.74), indicating different diagnostic accuracy.
For biostatistics questions involving combined diagnostic tests, remember that parallel testing (positive if either test positive) typically increases sensitivity at the cost of specificity, while series testing (positive only if both tests positive) does the opposite. Always check whether the combined AUC supports the claimed performance change.
- Based on the ROC curve shown, what is the approximate AUC value?
Answer: 0.75
The ROC curve shows moderate discriminatory ability, passing through approximately (0.25, 0.65) and (0.45, 0.80), which corresponds to an AUC of approximately 0.75. Choice B underestimates the area under the curve. Choice C overestimates the performance. Choice D would represent a diagonal line (random chance). Choice E would represent near-perfect discrimination with the curve hugging the upper-left corner.
- A meta-analysis reports that a screening test has a pooled AUC of 0.76 across 15 studies. However, individual study AUCs ranged from 0.62 to 0.89 with significant heterogeneity (I² = 78%). What is the most appropriate interpretation of these findings for clinical application?
Answer: The test shows moderate performance on average, but substantial variation suggests population-specific validation needed
High heterogeneity (I² = 78%) indicates substantial variation between studies that cannot be attributed to chance alone. While the pooled estimate suggests moderate diagnostic performance, the wide range (0.62-0.89) indicates the test's performance varies significantly across different settings or populations. This suggests need for population-specific validation rather than universal application. Choice A ignores the heterogeneity implications. Choice B is too extreme; meta-analysis can still provide useful information. Choice D incorrectly attributes variation to measurement error.
- An emergency department implements a new triage protocol using a severity score. The ROC analysis shows AUC = 0.73 for predicting need for immediate intervention. At what point on the curve would you expect to find the threshold that maximizes the sum of sensitivity and specificity?
Answer: The point closest to the upper-left corner of the ROC space
ROC curve analysis is fundamental for evaluating diagnostic tests, and understanding how to optimize the discrimination threshold is crucial for clinical decision-making.
The point that maximizes the sum of sensitivity and specificity corresponds to the point on the ROC curve that is closest to the upper-left corner (coordinate 0,1) of the ROC space. This represents the optimal balance between correctly identifying true positives (sensitivity) and true negatives (specificity). Mathematically, this point minimizes the distance to the "perfect classifier" corner where sensitivity = 1 and specificity = 1. This is why answer A is correct.
Answer B is incorrect because the point where sensitivity equals specificity doesn't necessarily maximize their sum. This intersection might occur at suboptimal performance levels, especially for tests with moderate discriminative ability like this one (AUC = 0.73).
Answer C represents the point of random chance, where the test performs no better than flipping a coin. At this intersection, sensitivity + specificity = 1, which is far from optimal.
Answer D confuses the steepest slope with optimal performance. While steep slopes indicate good discrimination at that threshold, the steepest point doesn't necessarily maximize the sum of sensitivity and specificity.
Study tip: Remember that the upper-left corner of ROC space represents perfection (100% sensitivity, 100% specificity). The closer your threshold gets to this corner, the better your combined performance. Visualize drawing the shortest line from any point on your ROC curve to that upper-left corner—that's your optimal threshold.
- An ROC curve analysis shows that a biomarker has AUC = 0.58 with 95% confidence interval (0.52, 0.64). The study included 200 cases and 200 controls. What is the most appropriate interpretation?
Answer: The biomarker shows poor discriminatory ability and is not significantly better than random chance
ROC curve analysis measures how well a test distinguishes between two groups (cases vs. controls). The Area Under the Curve (AUC) ranges from 0.5 (no discriminatory ability, equivalent to random chance) to 1.0 (perfect discrimination).
With an AUC of 0.58, this biomarker shows only minimal improvement over random guessing. More importantly, the 95% confidence interval (0.52, 0.64) includes 0.5, meaning we cannot statistically conclude that this biomarker performs better than chance alone. The sample size of 400 total subjects (200 cases, 200 controls) is actually quite adequate for AUC estimation, making these results reliable.
Answer A correctly identifies both the poor discriminatory ability (AUC barely above 0.5) and the lack of statistical significance (confidence interval includes 0.5). Answer B makes the common error of thinking any AUC above 0.5 indicates good performance—the key is whether it's significantly above 0.5. Answer C misinterprets the confidence interval; it actually includes 0.5 (from 0.52 to 0.64), not excludes it, so we cannot claim statistical significance. Answer D incorrectly suggests inadequate sample size, but 400 subjects provides sufficient power for reliable AUC estimation.
Study tip: For ROC analysis, always check two things: (1) Is the AUC clinically meaningful (generally ≥0.7 for acceptable discrimination)? (2) Does the confidence interval exclude 0.5 to establish statistical significance? Both conditions should be met for a useful biomarker.
- Based on the partial ROC curve data in the table, what can be concluded about the test's performance characteristics?
Answer: The test shows decreasing marginal benefit as false positive rate increases, with most discriminatory power at low false positive rates
The curve shows steep rise initially (FPR 0.05→0.15, sensitivity 0.20→0.55) then levels off (FPR 0.25→0.35, sensitivity 0.70→0.80), indicating most discriminatory power at low FPR with diminishing returns. This is typical of good diagnostic tests. Choice B incorrectly characterizes this as poor discrimination. Choice C misidentifies an 'optimal' point without clinical context. Choice D incorrectly describes the clearly non-linear relationship. Choice E is wrong because partial data can reveal performance characteristics.
